Stem Cell Covid Recovery Treatment

covid recovery treatment, covid stem cell treatment, post covid treatment, covid recovery treatment bangkok,

Post Covid Recovery Treatment:

Umbilical Cord tissue-derived MSCs (Mesenchymal Stem Cells), have been shown to improve Long Covid and post COVID-19 symptoms by significantly decreasing inflammatory cytokines, modulating the immune system and improving recovery times.

Post COVID-19 syndrome (Long Covid)

Similarly to post-acute viral syndromes described in survivors of other virulent coronavirus epidemics, there are increasing reports of persistent and prolonged effects after acute COVID-19. Patient advocacy groups, have helped contribute to the recognition of post-acute COVID-19, a syndrome characterized by persistent symptoms and/or delayed or long term complications beyond 4 weeks from the onset of symptoms.

Research suggests that 50 to 80 percent of people who recover from COVID-19 experience at least some lingering after-effects 3 months after infection with the coronavirus.

Prolonged symptom duration and disability are common in adults hospitalized with a severe form of COVID-19.

Patient interviews show that while 65 percent of people who had been released from the hospital after being treated for a severe form of COVID-19 had returned to full health, 35 percent still had not fully recovered more than 2 weeks after being hospitalized.

Long-Haul COVID-19 Symptoms

‍• fatigue
• body aches
• shortness of breath
• difficulty concentrating
• headache
• loss of taste or smell

Mesenchymal Stem Cell Therapy for COVID-19

Since the COVID-19 pandemic began there have been many studies conducted that aim to determine safety and explore efficacy of umbilical cord mesenchymal stem cell (UC‐MSC) infusions in subjects with COVID‐19. Mesenchymal stem cells administered intravenously may be able to significantly reduce significant adverse reactions, mortality, and time to recovery, in COVID-19 patients.

Treatment goals

The therapeutic uses of stem cells as a potential therapy for a variety of diseases has been immensely explored, the number of clinical trials conducted with Mesenchymal Stem Cells has increased exponentially over the past few years.

The stated primary goal of our protocol is the marked reduction in the levels of chronic low-grade inflammation for an extended period of time.

Stem cells have a unique, intrinsic property that attracts them to inflammation in the body. Studies have shown that stem cells can regenerate damaged or diseased tissues, reduce inflammation and modulate the immune system promoting better health and quality of life.

In regards to post-acute COVID-19 syndrome, patients can expect fewer long term complications, improved recovery time, a reduction in persistent COVID-19 related symptoms & an overall decrease in inflammation throughout the body.